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α-conotoxins PnIA and [A10L]PnIA stabilize different states of the
α7-L247T nicotinic acetylcholine receptor
Abstract

The effects of the native α-conotoxin PnIA, its synthetic derivative [A10L]PnIA and alanine scan derivatives
of [A10L]PnIA were investigated on chick wild type α7 and α7-L247T mutant nicotinic acetylcholine
receptors (nAChRs) expressed in Xenopus oocytes. PnIA and [A10L]PnIA inhibited acetylcholine (ACh)activated currents at wtα7 receptors with IC50 values of 349 and 168 nM, respectively. Rates of onset of
inhibition were similar for PnIA and [A10L]PnIA; however, the rate of recovery was slower for [A10L]PnIA,
indicating that the increased potency of [A10L]PnIA at α7 receptors is conveyed by its slower rate of
dissociation from the receptors. All the alanine mutants of [A10L]PnIA inhibited ACh-activated currents at
wtα7 receptors. Insertion of an alanine residue between position 5 and 13 and at position 15 significantly
reduced the ability of [A10L]PnIA to inhibit ACh-evoked currents. PnIA inhibited the non-desensitizing
ACh-activated currents at α7-L247T receptors with an IC50 194 nM. In contrast, [A10L]PnIA and the
alanine mutants potentiated the ACh-activated current α7-L247T receptors and in addition [A10L]PnIA
acted as an agonist. PnIA stabilized the receptor in a state that is non-conducting in both the wild type and
mutant receptors, whereas [A10L]PnIA stabilized a state that is non-conducting in the wild type receptor and
conducting in the α7-L247T mutant. These data indicate that the change of a single amino acid side-chain, at
position 10, is sufficient to change the toxin specificity for receptor states in the α7-L247T mutant.
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Conotoxins are short peptides isolated from the venom of
predatory marine snails of the genus Conus. Many of these
toxins are selective inhibitors of ligand- and voltage-gated ion
channels and are classified according to the type of channel to
which they bind. This high selectivity of the conotoxins has lead
to a great interest in the use of these molecules as pharmacological tools and the design of novel therapeutics. Much of this
work has been summarized in several recent reviews (1, 2). The
␣-conotoxins are between 11 and 16 amino acids in length and
are selective inhibitors of nicotinic acetylcholine receptors
(nAChRs),1 see Refs. 3 and 4 for review. Native nAChRs are
composed of a number of distinct subunits, which combine to
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The abbreviations used are: ACh, acetylcholine; nAChR, nicotinic
ACh receptor; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N⬘,N⬘-

form functional receptors each with distinct pharmacological
properties. The ␣-conotoxins contain 4 cysteines, which in their
natural conformation form disulphide bridges giving the molecule a globular two-loop configuration with sidechains projecting from a rigid backbone. The ␣-conotoxin PnIA, isolated from
the molluscivourous cone snail Conus pennaceus, is 16 amino
acids long, and the x-ray crystal structure shows an ␣-helix
between residues 5 and 12 and a 310 helical turn at the Nterminal end (5). PnIA has been demonstrated to be a competitive inhibitor of native nAChRs in cultured Aplysia neurons
(6), dissociated neurons from rat parasympathetic ganglia (7),
and recombinant nAChRs expressed in Xenopus oocytes (8)
with poor selectivity between receptor subtypes. A leucine for
alanine substitution at position 10 makes the toxin a highly
selective inhibitor of the ␣7 nAChR subtype (7, 8), see Table I.
Since the A10L mutation in PnIA changes the selectivity of the
toxin for receptor subtypes, it is also possible that the mechanism of inhibition differs between PnIA and [A10L]PnIA, the
A10L mutation may cause the toxins to have different affinities
for different states of the receptor.
The nAChRs have been presented as a prototype of allosteric
membrane protein (9) as described by the Monod-WymanChangeux model of allosteric interactions (10) in which the
structure of the molecule moves in concerted transitions between pre-existing conformational states. The protein can exist
in different states and undergoes spontaneous conformational
transitions, in the absence of a ligand the equilibrium between
these conformational states is in favor of the resting (closed)
state. Exposure to an agonist preferentially stabilizes the receptor in the active (open) and desensitized (closed) states,
whereas the binding of an antagonist molecule binds to and
stabilizes the molecule in a closed (resting or desensitized)
state (see Ref. 11). In such a model, transition from one state to
another depends upon both the presence of a ligand and/or the
isomerization coefficient, which governs changes between
states. Binding of a molecule at a site distinct from the agonistbinding site may modify the isomerization coefficient, thus
affecting agonist or antagonist behavior. Molecules acting in
this way are known as allosteric effectors (10).
To test whether mutations of PnIA affected the inhibitory
mechanism of the toxin, we examined the effects of PnIA,
[A10L]PnIA and alanine scan mutants of [A10L]PnIA at wild
type homomeric chick ␣7 receptors (wt␣7) and at chick ␣7
receptors with the L247T mutation (␣7-L247T) expressed in
Xenopus oocytes. ␣7-L247T receptors display non-desensitizing
currents in response to agonist application (12–16). Because it
was proposed that the L247T mutation renders conductive one
of the desensitized states (12), this mutant receptor can be used
as a tool to determine whether the same closed state of the
tetraacetic acid acetoxymethyl ester; HPLC, high performance liquid
chromatography; MLA, methyllycaconitine.
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The effects of the native ␣-conotoxin PnIA, its synthetic derivative [A10L]PnIA and alanine scan derivatives of [A10L]PnIA were investigated on chick wild
type ␣7 and ␣7-L247T mutant nicotinic acetylcholine
receptors (nAChRs) expressed in Xenopus oocytes. PnIA
and [A10L]PnIA inhibited acetylcholine (ACh)-activated
currents at wt␣7 receptors with IC50 values of 349 and
168 nM, respectively. Rates of onset of inhibition were
similar for PnIA and [A10L]PnIA; however, the rate of
recovery was slower for [A10L]PnIA, indicating that the
increased potency of [A10L]PnIA at ␣7 receptors is conveyed by its slower rate of dissociation from the receptors. All the alanine mutants of [A10L]PnIA inhibited
ACh-activated currents at wt␣7 receptors. Insertion of
an alanine residue between position 5 and 13 and at
position 15 significantly reduced the ability of
[A10L]PnIA to inhibit ACh-evoked currents. PnIA inhibited the non-desensitizing ACh-activated currents at ␣7L247T receptors with an IC50 194 nM. In contrast,
[A10L]PnIA and the alanine mutants potentiated the
ACh-activated current ␣7-L247T receptors and in addition [A10L]PnIA acted as an agonist. PnIA stabilized the
receptor in a state that is non-conducting in both the
wild type and mutant receptors, whereas [A10L]PnIA
stabilized a state that is non-conducting in the wild type
receptor and conducting in the ␣7-L247T mutant. These
data indicate that the change of a single amino acid
side-chain, at position 10, is sufficient to change the
toxin specificity for receptor states in the ␣7-L247T
mutant.

␣-Conotoxins Stabilize Different States of the ␣7-L247T nAChR
TABLE I
Sequences of ␣-conotoxins PnIA and [A10L]PnIA

EXPERIMENTAL PROCEDURES

Electrophysiology—Xenopus oocytes were prepared and injected as
described previously (17). Two-electrode voltage clamp recordings were
made 2–3 days after cDNA injection. During recordings the bath solution was OR2 medium containing (in mM), NaCl, 82.5; KCl, 2.5; CaCl,
2.5; MgCl, 1; atropine, 0.5; HEPES, 5, adjusted to pH 7.4 with NaOH.
ACh was applied in a fast flowing solution stream (⬃6 ml/min). Unless
indicated, oocytes were incubated in 100 M BAPTA-AM for at least 2 h
prior to recording. Two-electrode voltage clamp recordings were carried
out using a GeneClamp 500B amplifier (Axon Instruments Inc., Union
City, CA), recording electrodes contained 3 mM KCl and oocytes were
clamped at ⫺100 mV throughout the experiments. Experiments were
carried out at 18 °C. Dose-response curves for toxin inhibition were fit
with the equation y ⫽ 1/1 ⫹ ([toxin]/(IC50)n), where y is the normalized
response, [toxin] is the toxin concentration, and n is the Hill coefficient.
Measurements of rates of toxin block and recovery were carried out at
toxin concentrations close to the IC50. Data points for onset of block
were fit with the equation y ⫽ A e⫺t/ ⫹ B, where A ⫽ control amplitude
normalized to 1, B ⫽ current amplitude following block expressed as a
fraction of the control current, and t ⫽ time. Curves were fit using a 2
minimization fitting routine in Microcal origin 5.0 (Microcal software
inc.). Data are presented as mean ⫾ S.E.
Toxin Synthesis—The 16-residue peptides were synthesized manually on a 0.50-mmol scale using HBTU activation of t-butoxycarbonylamino acids with in situ neutralization chemistry as described previously (18). The syntheses were performed on p-methylbenzhydrylamine
resin using standard amino acid side chain protection. Each residue
was coupled for 10 min and coupling efficiencies determined by the
quantitative ninhydrin reaction (18). Prior to a standard HF cleavage
(10 ml of p-cresol:p-thiocresol:HF 1:1:8 (0 °C, 2 h) and workup (18), the
N-terminal t-butoxycarbonyl protecting group was removed (100% trifluoroacetic acid), and the resin was successively washed with dimethylformamide and dichloromethane. Air oxidations were carried out by
dissolving the lyophilized purified A10L[PnIA] analogues in 0.1 M
NH4HCO3/isopropyl alcohol (pH 8.25) with vigorous stirring at room
temperature overnight. Prior to purification the solution was acidified
to pH 3 with trifluoroacetic acid and analyzed by analytical C4 HPLC
using a linear gradient of 0 – 80% solvent B at 1%/min while monitoring
by UV absorbance at 214 nm and electronspray mass spectrometry.
Oxidized material was then purified by semipreparative HPLC using
the same chromatographic conditions.
RESULTS

PnIA and [A10L]PnIA Inhibit ACh-induced Currents at
Chick ␣7 nAChR Receptors—The effects of PnIA were investigated on chick ␣7 nAChR receptors expressed in Xenopus oocytes. Membrane currents were activated with 200 M ACh,
which is close to the EC50 (115 M) for these receptors (19).
2
R. C. Hogg, G. Hopping, P. F. Alewood, D. J. Adams, and D.
Bertrand, unpublished results.

PnIA inhibited ACh-induced currents in a concentration-dependent and reversible manner (Fig. 1A). The dose-response
relationship is shown in Fig. 1B; the fitted curve had an IC50 of
349 nM and a slope of 1.8.
The position 10 mutant of PnIA, [A10L]PnIA, has previously
been reported to inhibit ACh-induced currents at rat ␣7 receptors expressed in Xenopus oocytes (8) and native ␣7 receptors in
rat parasympathetic ganglion neurons (7). [A10L]PnIA was
twice as potent as PnIA to inhibit ACh-activated currents at
chick ␣7 receptors (Fig. 1C). Dose-response relationship was fit
by a curve with an IC50 value of 168 nM and a slope of 1.55
(Fig 1D).
Rate of Block and Recovery—The rate of onset and recovery
from block of ACh-activated currents at ␣7 receptors was measured for PnIA and [A10L]PnIA. As PnIA competes with ACh at
the binding site, ACh was applied for 2 s, and it was assumed
that these short applications of ACh did not displace the toxin.
Toxin concentrations used were close to the respective IC50
values. The rate of block with PnIA (400 nM) followed an exponential time course with a onset of 11.3 s (Fig. 2A).
An exponential rate of block and recovery would suggest that
the reaction is bimolecular. However, as the Hill coefficient for
PnIA inhibition is greater than unity (Fig. 1B), more than one
toxin binding site must be present. Since the homomeric ␣7
receptor contains five putative agonist binding sites, we tried to
fit the data using a scheme similar to MLA blockade of the ␣7
receptor (20). If the occupation of a single binding site is sufficient to prevent activation of the receptor by an agonist, then
the onset of block will follow an exponential time course. However, recovery from block requires that all of the binding sites
are unoccupied, causing an initial lag in the recovery. Palma et
al. (20) found that the recovery of block from MLA was best fit
by a five-site model. Since the time course of recovery from
MLA inhibition is ⬃10-fold slower than recovery from
[A10L]PnIA and more than 20-fold slower than PnIA, this
makes it likely that any lag in the recovery would not be
resolved at our sampling interval of 1, 5, and 10 s. Thus the
recovery describes only the dissociation of the last toxin molecule from the receptor. The time to half-recovery from PnIA
inhibition was in the region of 15 s. The onset of block of
[A10L]PnIA (200 nM) also followed an exponential time course
with a onset of 12.0 s and had a slower half-recovery time in the
region of 70 s (Fig. 3, C and D).
Fitting the data with a five site model (see Equation 3 from
Ref. 20), using approximate rates of Koff and Kon from Fig. 2, A
and B, and Fig. 3, A and B, did not describe the data better than
the Hill equations in Fig. 1, B and D, indicating that this model
is not appropriate to describe the interaction of PnIA and
[A10L]PnIA with the receptor. The observation that brief (0.5
or 1 s) applications or low concentrations of PnIA and
[A10L]PnIA increased the peak current amplitude above control values indicate that the scheme involving binding is complex, and this may affect the fit to the data.
[A10L]PnIA Alanine Mutants—To investigate the contribution of amino acid side chains in the [A10L]PnIA molecule to
the inhibitory potency at ␣7 receptors, we examined a series of
alanine mutants of [A10L]PnIA. All alanine mutants of
[A10L]PnIA significantly inhibited currents at wt␣7 receptors
(p ⬍ 0.05). Fig. 4 shows a comparison of the inhibitory effects of
the [A10L]PnIA alanine mutants (200 nM) on chick ␣7 nAChRs.
Removal of the projecting side chains between position 5 and 13
and at position 15, by the insertion of an alanine residue,
significantly reduced the potency of 200 nM [A10L]PnIA to
inhibit ACh-evoked currents (p ⬍ 0.05).
PnIA and [A10L]PnIA Have Different Effects on ␣7-L247T
Receptors—The ability of PnIA and [A10L]PnIA to inhibit cur-
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receptor is stabilized by PnIA and [A10L]PnIA, allowing us to
probe states of the receptor which are otherwise electrophysiologically silent in the wild type receptor. To test the contribution of projecting side-chains at other positions to the activity of
[A10L]PnIA, we have replaced each of the residues in turn with
an alanine to observe the effects of this mutation on toxin
activity. Circular dichroism spectra and 1H NMR experiments
have shown that substitution of individual residues in
[A10L]PnIA with an alanine do not result in perturbation of the
global fold,2 thus, any changes in activity in these molecules
can be directly correlated to the interactions of the projecting
side chains with the nAChR.
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rents mediated by the wt␣7 receptor indicates that they stabilize a state of the receptor which is non-conducting. Since the
A10L mutation changes the selectivity of the toxin for receptor
subtypes (7, 8), it is possible that the mechanism of inhibition
may also be different. In the minimal hypothetical gating
scheme for a nAChR shown in Fig. 5, this could be either the
resting or the desensitized state (D), which are both non-conducting in the wt␣7 receptor.
To investigate whether PnIA and [A10L]PnIA stabilize the
same state of the receptor, we used the chick ␣7 receptor
containing the L247T mutation. ␣7-L247T receptors display
non-desensitizing currents in response to ACh, and it has been
proposed that the L247T mutation causes one of the desensitized states of the receptor to become conducting (12); this
desensitized open state is represented as D* in Fig. 5 and could
account for the non-desensitizing current. It has been proposed
that it is this state of the receptor that is stabilized by nAChR
antagonists, such as DH␤E, which activate currents at this
receptor (14). Occasionally, slow desensitization of ␣7-L247T
receptors is observed, making it likely that other desensitized
non-conducting states of the receptor also exist. The ␣7-L247T
receptors exhibited a slowly activating, non-desensitizing current in response to ACh which reached a plateau within ⬃10 s.
␣7-L247T receptors show an increased sensitivity to ACh compared with wild type receptors with an EC50 of 0.62 M (14, 19).
PnIA inhibited the ACh-induced current through ␣7-L247T
receptors in a concentration-dependent and reversible manner
(Fig. 6A). The dose-response relationship was fit by a curve
with an IC50 of 194 nM and a slope of 0.9 (Fig. 6B).

A proportion of the ␣7-L247T receptors are spontaneously
active (14). PnIA also inhibited the spontaneously active “leak”
current ␣7-L247T receptors in a concentration-dependent manner (data not shown). In contrast to the inhibitory effect of
PnIA at ␣7-L247T receptors, co-application of [A10L]PnIA further activated the ACh-evoked current (Fig. 6C), suggesting
that [A10L]PnIA and the alanine mutants stabilize a conducting state of the receptor. All the alanine mutants of
[A10L]PnIA had a similar activating effect on the ACh-evoked
currents at the ␣7-L247T receptors (see Fig. 6C and Table II).
[A10L]PnIA (200 nM) increased the ACh-activated current to
1.79 ⫾ 0.09 times control (n ⫽ 9). The mean amplitude of the
[A10L]PnIA-activated current was 307 ⫾ 196 nA (n ⫽ 9).
[A10L]PnIA was also able to evoke a current at ␣7-L247T
receptors in the absence of ACh (Fig. 6D), further suggesting
that [A10L]PnIA stabilizes an “open state” of the receptor.
DISCUSSION

The aim of this study was to investigate the molecular interactions between ␣-conotoxins and the ␣7 nAChR and to determine
what effect these have on toxin activity. To this end, we have used
a series of mutated toxins and compared their effects on wild type
and mutant nAChRs to determine whether mutation of the native
toxin changes the mechanism of inhibition, in particular the affinity for different states of the receptor. We have examined which
amino acid side chains might be responsible for determining specificity of binding to different receptor states.
PnIA and [A10L]PnIA both inhibit ACh-evoked currents at
wt␣7 receptors. [A10L]PnIA was approximately twice as potent
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FIG. 1. Effect of PnIA and [A10L]PnIA on ACh-activated currents in wt␣7 receptors. A, PnIA inhibits ACh-activated currents in wt␣7
receptors in a concentration-dependent manner. B, the curve fit to the data had an IC50 of 349 nM and a Hill coefficient of 1.8. C, [A10L]PnIA
inhibits ACh-activated currents with an IC50 of 168 nM; the inhibition curve for PnIA has been superimposed for comparison. D (dashed line), Hill
coefficient was 1.55. Currents were activated with 200 M ACh.
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as PnIA. The rates of onset of block were similar for both
toxins, whereas recovery from block was slower for
[A10L]PnIA. These data suggest that the greater potency of
[A10L]PnIA at ␣7 receptors is conveyed by a slower rate of
dissociation from the receptor. The rate of bath exchange was ⬍
1 s, which is rapid compared with the onset of inhibition,
making it unlikely that the rate of toxin binding is diffusion
limited. A similar difference in off rates of PnIA and
[A10L]PnIA has been observed at cloned rat ␣7 receptors (8).
Attempts to describe toxin blockade using the model proposed
for MLA inhibition of ␣7 receptors revealed that marked differences in the profile of recovery as well as steady-state inhibition exist between ␣-conotoxin inhibition and MLA. The absence of a lag phase at the onset of the recovery can be
attributed to either reflecting profound differences in the mechanism of inhibition or as an inability to resolve the recovery
phase with adequate time resolution. Interestingly, Luo et al.
(8) have previously shown that both the onset and recovery of
PnIA and [A10L]PnIA blockade can be fitted with a single
exponential. However, the Hill coefficient greater than unity
observed for the steady-state dose-response inhibition indicates
that the toxin inhibition cannot be described by a simple bimolecular reaction.
NMR analysis has shown that the A10L substitution in PnIA
does not affect the backbone structure of the molecule or the
angle of the projecting side chains (7); therefore, this increase
in potency must be attributed to the longer aliphatic side chain
of the leucine at position 10. The circular dichroism spectra of
the [A10L]PnIA mutants were unchanged with regard to the
native toxin, indicating that the ␣-helix is still present.2
All alanine mutants of [A10L]PnIA inhibited ACh-evoked

currents at wt␣7 receptors. The potency profile of these toxins
indicates that removal of the projecting amino acid side chains
between position 5 and 13 and at position 15, by the insertion
of an alanine residue, reduced the potency of the [A10L]PnIA
mutants to inhibit ACh-evoked currents at wt␣7 receptors. The
pairwise interactions involved in the binding of PnIA and PnIB
to the human ␣7/5HT-3 receptor has been investigated by
mutant cycle analysis combined with a competitive binding
assay (21). The sequences of PnIB and [A10L]PnIA are similar,
differing only by a single serine in place of the asparagine
residue at position 11. The residues at positions 4, 5, 6, 7, 9, and
10 were found to endow PnIB with an affinity for the ␣7/5HT-3
receptor. This study reported a dominant interaction between
the leucine at position 10 and Trp-149 in loop B of the positive
face of the ACh binding site, which anchors the toxin to the
receptor, and also interactions between the proline residues at
positions 6 and 7 of the toxin with the receptor. Data from the
present study indicates that side chains projecting from the
helical central portion of the molecule contribute to the functional blocking activity of [A10L]PnIA at ␣7 receptors. Since
the previous study measured toxin binding in the absence of
agonist (21) and the present study functional activity, it is
possible that the toxin may be binding to different resting or
desensitized states of the receptor. The modification of the
projecting side chains may change the affinity of the toxin to
stabilize the receptor in alternative closed states.
The presence of a longer aliphatic side chain at position 10 in
PnIA has been reported to increase the affinity of the toxin for
␣7 receptors (21). Functional studies have shown that A10L
mutation in PnIA makes the resulting [A10L]PnIA toxin more
selective for ␣7 receptors (7, 8). To determine whether this
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FIG. 2. Time course of block and recovery from block of PnIA at wt␣7 receptors. A, 400 nM PnIA progressively inhibited ACh-induced
responses (200 M). B, the time course of onset of block was fit by a single exponential with a  of 11 s. C, recovery of ACh-induced current amplitude
upon washout of PnIA. D, time course of recovery of current amplitude from block by 400 nM PnIA. n ⫽ 5 for each data point.
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FIG. 4. Relative inhibition of ACh-induced currents at wt␣7
receptors by PnIA, [A10L]PnIA, and alanine analogues. Control
current amplitudes in the absence of toxin have been normalized to 1.0.
All toxins were applied at 200 nM, and currents were activated by 200
M ACh. The number of experiments is given in brackets, and asterisks
indicates values significantly different from [A10L]PnIA (p ⬍ 0.05).

mutation also changes the affinity of the toxin for different
states of the ␣7 receptor, we used the ␣7-L247T mutant receptor. Two models have been proposed to account for the nondesensitizing behavior of the L247T mutant. One is that the
desensitized state of the receptor becomes conducting, and

FIG. 5. Hypothetical gating scheme for the nAChR. The nAChR
is assumed to exist in multiple interconvertible states, a closed resting
state, an open conducting state, and at least one desensitized state. In
wild type receptors the desensitized states are non-conducting; however, we propose that in the ␣7-L247T receptor one of the desensitized
states (D*) of the receptor is conducting.

another proposes that the isomerization coefficient is altered
favoring the open state (22–24). However, this second scheme
does not adequately describe how antagonists of the wt␣7 receptor can act as agonists at the mutant receptor. If we assume
the first model, in which the toxin is stabilizing the desensitized state of the receptor, we would expect to see a much
reduced block at the ␣7-L247T receptor.
PnIA potently inhibited ACh-induced currents at ␣7-L247T
receptors, indicating that, as for MLA and ␣-bungarotoxin, it
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FIG. 3. Time course of block and recovery from block of [A10L]PnIA at wt␣7 receptors. A, 200 nM [A10L]PnIA inhibited responses to
ACh (200 M). B, data points for the time course of onset of block were fit by single exponential curve with a  value of 12 s. C, recovery of
ACh-induced current amplitude upon washout of [A10L]PnIA. D, time course of recovery from block was significantly slower with a half-recovery
time in the region of 70 s, n ⫽ 4 for each data point. Dashed line represents the recovery from block with PnIA.
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TABLE II
Effect of ␣-conotoxins on ACh-activated currents
at ␣7-L247T receptors
Toxin

Activation

[A10L]PnIA
G1A
S4A
L5A
P6A
P7A
PnIA
N11A
N12A
P13A
D14A
Y15A

⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹

Inhibition

⫹

probably stabilizes the receptor in the resting state. However,
in contrast, [A10L]PnIA and the [A10L]PnIA alanine scan mutants all potentiated the ACh-induced responses at the ␣7L247T receptors. In addition, [A10L]PnIA was able to activate
a current at ␣7-L247T receptors in the absence of ACh. Since
[A10L]PnIA potently inhibits currents at wt␣7 receptors but
potentiates currents at the ␣7-L247T mutant, we conclude that
[A10L]PnIA is stabilizing the desensitized state of the receptor
that is non-conducting in the wt␣7 receptor but conducting in
the ␣7-L247T mutant. PnIA stabilizes the receptor in a state
that is non-conducting in both receptors, which would corre-

spond to the resting state. The ability of all the toxins containing the [A10L] mutation to potentiate the currents at ␣7-L247T
receptors indicates the presence of the longer lysine side chain
at position 10 alone is sufficient to change the specificity of the
toxin to bind and stabilize the ␣7-L247T receptor in different
states, and this is not affected by other mutations. The observation that the amplitude of the ACh-induced current at wt␣7
receptors was increased following short 0.5–1-s applications of
PnIA and [A10L]PnIA (Figs. 2A and 3A) suggests both toxins
bind to the resting state of the receptor at low concentrations
and increase the ratio of receptors that are in the resting as
compared with the desensitized state. This effect supports the
hypothesis that PnIA is stabilizing the resting state of the
receptor, but also suggests that at low concentrations
[A10L]PnIA may also have some affinity for a resting state of
the receptor. However, since the resting and desensitized
states of the wt␣7 receptor are both non-conducting, there is no
way to confirm that [A10L]PnIA stabilizes the same state in
the wt␣7 and ␣7-L247T receptor.
Fig. 4 illustrates that the removal of side chains from residues between positions 5 and 13 reduce the potency of
[A10L]PnIA to inhibit currents at ␣7 receptors. However, it is
clear that that the removal of projecting side chains at positions other than position 10 does not affect the ability of
[A10L]PnIA to potentiate responses at ␣7-L247T receptors.
While demonstrating unambiguously the ability of
[A10L]PnIA to stabilize the desensitized open state of the ␣7-
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FIG. 6. PnIA inhibits the ACh-evoked current in ␣7-L247T mutant receptors, whereas [A10L]PnIA and the alanine mutants
facilitate ACh-induced responses. A, PnIA inhibits non-desensitizing ACh-evoked currents in ␣7-L247T receptors. B, concentration-response
relationship for inhibition had an IC50 of 194 nM, and ACh concentration was 0.5 M. C, PnIA, and [A10L]PnIA and alanine mutants, have different
effects on the ACh-evoked current at ␣7-L247T receptors; PnIA (200 nM) inhibits, while [A10L]PnIA (200 nM) activates, currents in the same oocyte.
S4A[A10L]PnIA also activates a current, while PnIA inhibits the ACh-evoked current. The black bar indicates the application of ACh (0.5 M), and
the open bar indicates the toxin application. Currents have been normalized and superimposed, and control current amplitude was 250 nA. D,
[A10L]PnIA (1 M) activates a current at ␣7-L247T receptors.
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L247T receptor, the rather complex form of the evoked current
indicates that a complex equilibrium must be stabilized by the
toxin. Since it is beyond the scope of this study to examine
these time courses in detail, no attempt was made to analyze
the profile of current decay.
This study highlights the usefulness of the ␣-conotoxins as
research tools, which can be subtly modified to probe the molecular interactions of ligand binding to nAChRs. The stability
of the peptide backbone to amino acid substitutions also makes
them ideal models to develop pharmacophores for nAChR subtypes, which may lead to the development of non-peptide modulators of nAChR function.
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